Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Dumaz

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Small Gtpases|February 1, 2012
Mechanism of RAF isoform switching induced by oncogenic RAS in melanomaNicolas Dumaz
Current Opinion in Oncology|December 17, 2020
New perspectives on targeting RAF, MEK and ERK in melanomaNicolas Dumaz, Céleste Lebbé
Molecular Cancer|February 20, 2018
The role of RICTOR downstream of receptor tyrosine kinase in cancersAhlem Jebali, Nicolas Dumaz
The Journal of Biological Chemistry|June 13, 2003
Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with RasNicolas Dumaz, Richard Marais
Molecular Cell|January 25, 2005
Raf phosphorylation: one step forward and two steps backNicolas Dumaz, Richard Marais
The FEBS Journal|July 13, 2005
Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in BrusselsNicolas Dumaz, Richard Marais
Current Opinion in Oncology|December 14, 2019
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanomaSamia Mourah, Baptiste Louveau, Nicolas Dumaz
Molecular and Cellular Biology|May 9, 2002
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanismsNicolas Dumaz, Yvonne Light, Richard Marais
Current Opinion in Oncology|December 14, 2019
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanomaJulie Delyon, Céleste Lebbe, Nicolas Dumaz
Medecine Sciences : M/S|October 27, 2011
[When CRAF takes over BRAF in melanoma]Nicolas Dumaz, Martine Bagot, Armand Bensussan
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Small Gtpases|February 1, 2012
Mechanism of RAF isoform switching induced by oncogenic RAS in melanomaNicolas Dumaz
Current Opinion in Oncology|December 17, 2020
New perspectives on targeting RAF, MEK and ERK in melanomaNicolas Dumaz, Céleste Lebbé
Molecular Cancer|February 20, 2018
The role of RICTOR downstream of receptor tyrosine kinase in cancersAhlem Jebali, Nicolas Dumaz
The Journal of Biological Chemistry|June 13, 2003
Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with RasNicolas Dumaz, Richard Marais
Molecular Cell|January 25, 2005
Raf phosphorylation: one step forward and two steps backNicolas Dumaz, Richard Marais
The FEBS Journal|July 13, 2005
Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft für Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in BrusselsNicolas Dumaz, Richard Marais
Current Opinion in Oncology|December 14, 2019
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanomaSamia Mourah, Baptiste Louveau, Nicolas Dumaz
Molecular and Cellular Biology|May 9, 2002
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanismsNicolas Dumaz, Yvonne Light, Richard Marais
Current Opinion in Oncology|December 14, 2019
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanomaJulie Delyon, Céleste Lebbe, Nicolas Dumaz
Medecine Sciences : M/S|October 27, 2011
[When CRAF takes over BRAF in melanoma]Nicolas Dumaz, Martine Bagot, Armand Bensussan
Pageof 5